MARLBOROUGH, Mass., September 14, 2021 – CardioFocus, Inc., a medical device
company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced
today that it has entered into an agreement with IsoLase Ltd. to acquire IsoLase’s patent
portfolio. The acquisition agreement includes US patents 8,992,514 and 10,517,669 and EU
patent 2 817 061B1 as well as several pending patents, all in the field of Afib ablation. Among
other things, these patents relate to the use of electrodes on a balloon for the ablation of Afib.
The acquisition of these patents strengthens CardioFocus’ existing HeartLight System
intellectual property portfolio. The HeartLight X3 System is CardioFocus’ catheter ablation
technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard
“CardioFocus is a pioneering innovator in the use of highly compliant balloons, direct
visualization and laser energy for the ablation of Afib” said Burke T. Barrett, chief executive
officer and president of CardioFocus. “The acquisition of this IP further strengthens the strong IP leadership position we have in this field.”
About the HeartLight X3 System
The HeartLight X3 System is a revolutionary catheter ablation technology for controlled and
consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (Afib). Using direct tissue visualization, titratable laser energy and compliant balloon technology, the HeartLight X3 System is a truly differentiated PVI solution. HeartLight is a treatment option for some patients whose AFib is insufficiently controlled with medication (1). More than 33 million patients worldwide suffer from AFib (2), which has been associated with significant symptoms, functional impairment, stroke, cognitive decline, heart failure, and reduced longevity. HeartLight X3 offers a unique RAPID mode, which leverages a precise motor control system that enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. Clinical studies of the HeartLight X3 System demonstrated that AFib patients can be treated quickly resulting in consistently reduced procedure times with excellent procedure time predictability. (3,4)
About CardioFocus, Inc.
Headquartered in Marlborough, MA, CardioFocus is a medical device innovator and
manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial
fibrillation (AFib), the most common heart arrhythmia. The HeartLight X3 catheter, endoscope, sheath, console and balloon fill media are all manufactured in the USA. For more information, visit http://www.CardioFocus.com.
1. In the United States, the HeartLight System is indicated to treat drug refractory, symptomatic, paroxysmal atrial fibrillation (AFib).
2. Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.
3. X3 total procedure time was statistically significantly shorter than the original HeartLight and irrigated radiofrequency ablation (RF) ablation based on a comparison to the original HeartLight pivotal study (historical control).
4. Predictability is determined by the standard deviation of the procedure time.